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Background: Rhinovirus (RV) is a major cause of chronic obstructive pulmonary disease (COPD) exacerbations, and
primarily infects bronchial epithelial cells. Immune responses from BECs to RV infection are critical in limiting viral
replication, and remain unclear in COPD. The objective of this study is to investigate innate immune responses to
RV infection in COPD primary BECs (pBECs) in comparison to healthy controls.
Methods: Primary bronchial epithelial cells (pBECs) from subjects with COPD and healthy controls were infected
with RV-1B. Cells and cell supernatant were collected and analysed using gene expression microarray, qPCR, ELISA,
flow cytometry and titration assay for viral replication.
Results: COPD pBECs responded to RV-1B infection with an increased expression of antiviral and pro-inflammatory
genes compared to healthy pBECs, including cytokines, chemokines, RNA helicases, and interferons (IFNs). Similar
levels of viral replication were observed in both disease groups; however COPD pBECs were highly susceptible to
apoptosis. COPD pBECs differed at baseline in the expression of 9 genes, including calgranulins S100A8/A9, and 22
genes after RV-1B infection including the signalling proteins pellino-1 and interleukin-1 receptor associated kinase 2.
In COPD, IFN-β/λ1 pre-treatment did not change MDA-5/RIG-I and IFN-β expression, but resulted in higher levels
IFN-λ1, CXCL-10 and CCL-5. This led to reduced viral replication, but did not increase pro-inflammatory cytokines.
Conclusions: COPD pBECs elicit an exaggerated pro-inflammatory and antiviral response to RV-1B infection,
without changing viral replication. IFN pre-treatment reduced viral replication. This study identified novel genes and
pathways involved in potentiating the inflammatory response to RV in COPD.
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Chronic obstructive pulmonary disease (COPD) is re-
sponsible for an increasing burden of illness and death
around the world. COPD is chronic airway disease, char-
acterized by incompletely reversible airflow obstruction,
and symptoms of cough and sputum production. These
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reproduction in any medium, provided the orinfections [1]. Rhinoviruses (RVs) are the most fre-
quently detected viruses during acute exacerbation [2],
and infection is associated with rapid decline in lung
function and severe symptoms that often requires
hospitalization [2]. However the specific mechanism that
leads to this enhanced susceptibility and severe symp-
toms following RV infection is not well understood.
Bronchial epithelial cells (BECs) are the primary site of
RV infection, where the infection occurs both in the
upper and lower respiratory epithelium equally [3]. RV
can infect other cells including airway macrophages,
however the virus does not replicate in these cells [4],
which demonstrates the important role of BECs in the
first line of defence against invading pathogens. As RVsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tially recognized by the RNA helicase melanoma
differentiation-associated gene −5 (MDA-5, also known
as IFIH1), which then signals for the induction of type I
interferon (IFN-α/β) and type III IFNs (IFN-λ1/2/3).
These IFNs then signal for the expression of over 300
IFN-stimulated genes (ISGs) including IFNs, CCL-5,
CXCL-10, and the RNA helicases MDA-5 and retinoic
acid-inducible gene–I (RIG-I or DDX58) [5]. These ISGs
amplify IFN responses and induce apoptosis and limit
viral replication. CCL-5 and CXCL-10 recruit cytotoxic
T cells to kill virus-infected cells [5].
RV RNAs are also recognized by toll-like receptor
(TLR) -3 and via nuclear factor – kappa B (NF-κB) sig-
nalling triggering the release of pro-inflammatory cyto-
kines such as IL-6, leading to acute inflammation and
fever [6]. Subjects with COPD are known to have
increased inflammatory cytokines that drive increased
recruitment of neutrophils due to heightened chemo-
attractant CXCL-8, and the neutrophils then phagocyt-
ose replicating viruses and limit viral spread [7].
However the mechanisms underlying the severe out-
comes to infection in COPD and the role of BECs
responses to virus infection remains unclear. Here we
hypothesized that primary BECs (pBECs) from COPD
subjects have an exaggerated inflammatory response and
abnormal antiviral response to RV infection compared
to healthy control pBECs. In this study, pBECs from
subjects with COPD and healthy controls were infected
RV-1B, and the immune responses to infection were
assessed using whole genome microarray analysis, allow-
ing the opportunity for discovery of novel regulators of
abnormal responses in COPD.
Methods
Rhinovirus
RV-1B was obtained from the American Tissue Culture
Collection (ATCC, USA). Virus was propagated using
RD-ICAM-1 cells, clarified by centrifugation and viral
titres were determined using 50% Tissue Culture Infect-
ive Dose (TCID50).
Subject recruitment
Subjects with COPD were recruited; defined by a previ-
ous smoking history and fixed airflow limitation on spir-
ometry with an FEV1/FVC ratio < 70%, and FEV1 < 80%
predicted and classified by the GOLD criteria. Those
with GOLD Stage III (severe COPD) FEV1 30 – 50%
predicted, and Stage IV (very severe COPD) FEV1 <30%
were included. COPD subjects were ex-smokers (at least
one year abstinent) and did not use inhaled corticoster-
oids for two weeks prior to bronchoscopy. Healthy
non-smoking controls with no evidence of airflow ob-
struction, bronchial hyper-responsiveness to hypertonicsaline challenge, or chronic respiratory symptoms were
recruited. A clinical history, examination and spirometry
were performed. Subjects were excluded if they had
symptoms of an acute respiratory tract infection a
month prior. All subjects gave written informed consent.
The study was approved by The University of Newcastle
Human Research Ethics.
Cell culture and viral infection
Human pBECs were obtained by endobronchial brushing
during fibre-optic bronchoscopy in accordance with
standard guidelines, and cultured as described previously
[8]. Cells were seeded at 1 x 105 and cultured in BEBM
basal media with supplements (BEGM, Lonza). At pas-
sage 2 when the cells reached 80% confluency in 24-well
plates, virus infection was performed at a multiplicity of
infection (MOI) of 20 for 1 hour with shaking. After 1
hour incubation viral inoculum was removed and fresh
BEBM basal media supplemented with 0.5% BSA was
then added. For IFN pre-treatment experiments, human
recombinant IFN-β (10U) and IFN-λ1 protein (1ng/mL;
R&D Systems) was used to pre-treat pBECs for 24hrs
before RV-1B infection in the designated experiments.
For all experiments samples were collected at 6hrs for
whole genome gene expression microarray and real-time
PCR (qPCR) and 24hrs for ELISA/CBA and viability/
apoptosis.
Whole genome gene expression microarray
pBEC RNA was extracted, 500ng amplified and 750ng
cRNA hybridised to Illumina’s HumanRef-8 V3 Bead-
Chips as previously described [9].
Real-time PCR (qPCR)
RNA was extracted, reverse transcribed to cDNA and
real-time PCR was performed as previously described
[9]. Briefly, RNA (200ng) was reverse-transcribed to
cDNA using the high capacity cDNA reverse transcrip-
tion kit (Applied Biosystems, Foster City,USA). Taqman
qPCR primer and probes for the target genes were pur-
chased in kit form (Applied Biosystems, Foster City,
USA). PCR primers and probes were combined with
Taqman gene expression master mix as per manufac-
turer’s instructions in duplicate singleplex real-time
PCRs (7500 Real Time PCR System, Applied Biosys-
tems). Fold change results were calculated using 2-ΔΔCt
relative to the internal reference gene (18S) and the
mean of all samples.
ELISA
IFN-λ1/3, CXCL-10, IL-6, TNF-α and CCL-5 concentra-
tion was assessed using ELISA kit (IFN-λ1/3, R&D Sys-
tems, lower detection limit of 31.25pg/mL) and cytometric
bead array (CXCL-10, IL-6, TNF-α and CCL-5, BD
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to the manufacturer’s instructions.
Viability/Apoptosis
Apoptosis was measured using Annexin V-PE Apoptosis
Detection Kit I (Becton Dickinson) according to manu-
facturer’s instructions [10]. Briefly, infected and non-
infected cells were stained with Annexin V-PE and
7-AAD analysed by flow cytometry. Annexin V-PE posi-
tive and 7-AAD negative were determined to be apop-
totic, Annexin V-PE and 7-AAD positive were necrotic
and Annexin V-PE and 7-AAD negative were live cells.
Viral replication
Viral replication was determined using both TCID50 and
relative RNA copy number using a standard curve cre-
ated using serial dilution of RV-1B RNA.
Data analysis
Data analysis preformed using Stata 9 or GraphPad Prism
5 and reported as mean with standard error of means
(SEM) for normally distributed data and median (quartile
[Q] 1, Q3) for nonparametric data. Statistical comparisons
were performed by using multiple comparisons ANOVA
for parametric data and the Kruskal-Wallis test for non-
parametric data. P<0.05 was considered significant.
Whole genome gene expression microarray analysis
Microarray data were exported by using Genome Studio
(Illumina) and analyzed by using GeneSpring GX11
(Agilent Technologies). Data were log-transformed, nor-
malized, and baseline-converted to the median of all
samples. Data were filtered, and only genes flagged as
present (< 0.05 detection P value) in all samples were
included in the further analysis. Hierarchical clustering
analysis was performed by using the Pearson centered
algorithm with complete linkage. The Pearson algo-
rithms cluster samples on the basis of their correlation
coefficients, whereas complete linkage measures that the
distance between 2 clusters is the greatest distance
between the members of the 2 clusters. Differential gene
expression was determined by using ANOVA with
Tukey post hoc testing (P < 0.05 adjusted for multiple
comparisons by using the Benjamini-Hochberg method)
and fold change >2.
Results
Gene expression profiles of healthy control and COPD
pBECs at baseline and in response to RV-1B infection
Primary BECs from ten subjects with moderate and se-
vere COPD and ten healthy controls were assessed
in vitro for their immune response to RV-1B infection.
Patient characteristics and details of optimisation of ex-
perimental conditions are summarised in Additional file1: Table S1 of the online supplement. Gene expression at
baseline of the non-infected media controls was first
examined and showed a different expression profile
between COPD and healthy pBECs (Table 1). There
were 9 genes that were highly up-regulated in COPD
pBECs, including genes involved in innate immunity, cell
repair, and some with protease/anti-protease activity.
Infection of pBECs with RV-1B led to changes in the
gene expression profile from baseline, and differences
between healthy and COPD pBEC responses were
assessed. RV-1B infection caused significant up-regulation
of 23 entities corresponding to 20 genes in healthy control
pBECs (Figure 1A), and 48 entities corresponding to 42
genes were significantly induced in COPD pBECs
(Figure 1B). Of the genes that were induced in both COPD
and healthy control pBECs, all were up-regulated to higher
levels in COPD compared to that in healthy pBECs
(Figure 1C). There was also an additional 22 genes up-
regulated in COPD pBECs in response to RV-1B infection
(Table 2).
RV-1B infection of COPD pBECs induced higher
inflammatory and antiviral responses compared to
healthy controls
Microarray analysis showed that COPD pBECs induced
an overall higher level of inflammatory and antiviral
gene expression after RV-1B infection (Additional file 1:
Table S2). The increase of selected genes detected by
microarray were further validated by qPCR and con-
firmed by ELISA at the protein level.
RV-1B infection in healthy pBECs did not cause an
up-regulation of the inflammatory genes IL-6 and
TNF-α, however RV-1B infection led to a significant up-
regulation of IL-6 (Figure 2A), but not TNF-α
(Figure 2B) from media control in COPD pBECs. RNA
helicases MDA-5 (Figure 2C) and RIG-I (Figure 2D)
were up-regulated after RV-1B infection of both healthy
and COPD pBECs, however the induction was signifi-
cantly higher in the COPD group. Induction of IFN-λ1,
and ISGs CCL-5 and CXCL-10 was significantly higher
in COPD pBECs after infection compared to that in
healthy pBECs (Figure 2F – H). IFN-β was only induced
in COPD pBECs after infection (Figure 2E).
All proteins were induced above media control and no
difference was observed at this baseline level between
healthy and COPD pBECs (data not shown). Both healthy
and COPD pBECs induced significant levels of IL-6 and
TNF-α at 24hr after RV-1B infection (Figure 3A – B), with
IL-6 being significantly higher in COPD pBECs. Similarly
IFN-λ1, CCL-5, and CXCL-10 protein was also signifi-
cantly higher in COPD than in healthy pBECs after RV-1B
infection (Figure 3C – E).
Surprisingly the high inflammatory and antiviral in-
duction in COPD pBECs did not affect viral replication
Table 1 Differential gene expression between baseline COPD pBECs and healthy control pBECs
SYMBOL GENE NAME FOLD CHANGE P value
Protease and Antiproteases
MMP10 Matrix metallopeptidase 10 2.94 0.0029
PI3 Peptidase inhibitor 3 (Elafin) 2.22 0.0287
ADAM19 ADAM metallopeptidase domain 19 2.13 0.0090
Innate immunity
S100A8 S100 calcium binding protein A8 2.63 0.0189
S100A9 S100 calcium binding protein A9 2.32 0.0143
Epithelial cell related processes
KRT6C Keratin 6C 10.01 0.0002
RHCG Rh family, C glycoprotein 2.51 0.0033
CNFN Cornifelin 2.23 0.0213
SPRR2E Small proline-rich protein 2E 2.15 0.0017
Figure 1 Cluster analysis of genes significantly induced in healthy (n=10) and COPD (n=10) pBECs 6 hours after RV-1B infection.
Microarray analysis showed that RV-1B infection significantly up-regulated (A) 20 genes in healthy controls and (B) 42 genes in COPD pBECs. (C)
All the genes that were up-regulated in both groups were significantly higher in COPD compared to that in healthy control pBECs.
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Table 2 Twenty two genes were increased in RV-1B infection of COPD pBECs but not changed RV-1B infection of
healthy pBECs
SYMBOL GENE NAME FOLD CHANGE P value PROBE ID
IFNB1 Interferon, beta 1 5.8 <0.0001 1510669
IL6 Interleukin 6 3.3 0.0022 4040576
RIG-I Retinoic acid-inducible gene – I 3.1 <0.0001 4760703
ATF3 Activating transcription factor 3 2.7 0.0007 4780128
CX3CL1 Chemokine (C-X3-C motif) ligand 1 2.5 <0.0001 630521
CXCL9 Chemokine (C-X-C motif) ligand 9 2.5 <0.0001 5570278
MDA-5 Melanoma differentiation-associated gene −5 2.5 <0.0001 4570441
ZC3HAV1 Zinc finger CCCH-type, antiviral 1 2.4 <0.0001 3710243 4540382
2.2 <0.0001
PMAIP1 Phorbol-12-myristate-13-acetate-induced protein 1 2.4 <0.0001 2750367
DHX58 DEXH (Asp-Glu-X-His) box polypeptide 58 2.3 <0.0001 3930681
NFS1 NFS1 nitrogen fixation 1 homolog 2.2 <0.0001 7570411
CH25H Cholesterol 25-hydroxylase 2.2 <0.0001 1770593
CCRN4L CCR4 carbon catabolite repression 4-like 2.2 <0.0001 460484
IRAK2 Interleukin-1 receptor-associated kinase 2 2.2 <0.0001 3930750
PELI1 Pellino homolog 1 2.2 0.0007 3450092
NCOA7 Nuclear receptor coactivator 7 2.1 0.0001 630091
PLAUR Plasminogen activator, urokinase receptor 2.1 0.0054 730528 6220671
2.1 0.0028
DDX60 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 2.1 0.0001 7610053
NFKBIZ Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta 2.1 0.0011 2470348
GBP4 Guanylate binding protein 4 2.1 <0.0001 1980524
EFNA1 Ephrin-A1 2.1 <0.0001 3390187
DUSP19 Dual specificity phosphatase 19 2.0 0.0019 5260195
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as viral RNA and viral titre at 24hr was similar in
healthy and COPD pBECs. RV-1B infection in both
healthy and COPD pBECs resulted in a significant de-
crease in cell viability (Additional file 1: Figure S2A of
the online supplement), however there was more apop-
tosis in the RV infected COPD pBECs (Additional file 1:
Figure S2B and E2C of the online supplement).
The heightened inflammatory response in COPD pBECs is
due to enhanced immune signalling caused by RV-1B
infection
In order to understand the mechanisms underlying the
increased immune responses in COPD pBECs, we fur-
ther examined the genes that are involved in immune
signalling and that were up-regulated greater than 2 fold
by RV-1B infection in COPD but not healthy pBECs
(Table 2). These genes were reviewed for their role in in-
nate immunity in published literature (Pubmed), and
those with known functions were mapped into the cur-
rently known intracellular innate immune signalling
pathways. Figure 4 illustrates the key novel innateimmune signalling genes involved in RV induced inflam-
matory responses in COPD pBECs. Signalling via IL-1
and TLR pathways was apparent, involving Pellino 1
(PELI1), IL-1 receptor-associated kinase-like 2 (IRAK2)
and cholesterol 25-hydroxylase (CH25H). Oxidative
stress appears important relating to the up-regulation of
activating transcription factor 3 (ATF3) and guanylate
binding protein 4 (GBP4), and phorbol-12-myristate-13-
acetate-induced protein 1 (PMAIP1 or Noxa) plays a
role in apoptosis (Figure 4).
Pre-treatment with IFN-β and IFN-λ1 led to enhanced
antiviral responses to RV-1B infection in both healthy and
COPD pBECs
COPD pBECs produced a greater antiviral response to
RV infection, but this was not associated with reduced
viral replication. We sought to determine if IFN-β/λ1
pre-treatment affects the inflammatory and antiviral
responses to RV-1B infection. pBECs were primed with
a combination of exogenous IFN-β and IFN-λ1 before
infection. IFN-β/λ1 pre-treatment led to a significant in-
duction of IL-6 and TNF-α mRNA in healthy control
Figure 2 Inflammatory and antiviral genes at 6 hours after RV-1B infection in healthy (n=10) and COPD (n=10) pBECs, confirmation of
the microarray findings. Inflammatory cytokines (A) IL-6 and (B) TNF-α were not induced by RV-1B infection in healthy control pBECs, but were
IL-6 was significantly up-regulated by infection in COPD pBECs, whilst TNF-α was significantly higher in the baseline media control and after RV
infection. RNA helicases (C) MDA-5 and (D) RIG-I and antiviral (E) IFN-β, (F) IFN-λ1, (G) CCL-5 and (H) CXCL-10 mRNA were all significantly higher
in RV infected COPD pBECs compared to healthy controls. Results are presented as mean fold change in expression with the error bar as
standard error of the mean (SEM). * p<0.05 versus the corresponding media control. ^ p<0.05 versus healthy RV infected pBECs.
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While the RNA helicases and IFN-β mRNA was signifi-
cantly up-regulated in healthy control pBECs by the pre-
treatment, these genes were not induced in COPD
pBECs following pre-treatment (Figure 5C – E). IFN-λ1,CCL-5, and CXCL-10 mRNA however were significantly
induced in both pBECs groups after IFNs pre-treatment
(Figure 5F – H). Surprisingly release of IL-6 and TNF-α
protein did not increase with the up-regulated gene ex-
pression. IL-6 protein was in fact reduced and TNF-α
Figure 3 Inflammatory and antiviral proteins at 24 hours after RV-1B infection in healthy (n=10) and COPD (n=10) pBECs. (A) IL-6
protein induction after infection was significantly higher in COPD pBECs however (B) TNF-α induction was not significantly different between
healthy and COPD pBECs. (C) IFN-λ1, (D) CCL-5 and (E) CXCL-10 protein induction in COPD pBECs was also significantly higher than that in
healthy pBECs. Results are presented as mean and the error bar as standard error of the mean (SEM). * p<0.05 versus healthy RV infected pBECs.
Figure 4 Key signalling molecules and pathways involved in RV induced inflammatory responses in COPD pBECs. Genes that were
identified to play a role in innate immune signalling that were increased in RV infected COPD pBECs include IRAK2, PELI1, CH25H, PMAIP1, ATF3
and GBP4. IRAK2, PELI1 and CH25H (bolded in box) are involved in signal transduction downstream of IL-1/TLR leading to NF-κB activation and
production of inflammatory cytokines. Induction of PMAIP1, a mitochondria-associated protein, leads to apoptosis. ATF3 senses cellular stress and
functions to reduce TLR4-mediated NF-κB signalling. GBP4 is an IFN-inducible GTPase that has been shown to disrupt IRF7 activation, thereby
inhibiting the induction of type I IFNs. Solid line indicates up-regulation, and dashed line indicates down-regulation.
Baines et al. Respiratory Research 2013, 14:15 Page 7 of 12
http://respiratory-research.com/content/14/1/15
Figure 5 Inflammatory and antiviral genes at 6 hours after RV-1B infection in IFN-β/λ1-pre-treated healthy (n=6) and COPD (n=6)
pBECs. IFN-β/λ1-pre-treatment before RV-1B infection resulted in a significant increase in (A) IL-6 and (B) TNF-α mRNA in healthy but not in
COPD pBECs. (C) MDA-5, (D) RIG-I, and (E) IFN-β mRNA was significantly induced and higher in healthy control than in COPD pBECs. In sharp
contrast, (F) IFN-λ1, (G) CCL-5, and (H) CXCL-10 mRNA was significantly up-regulated by IFNs pre-treatment in both healthy and COPD pBECs.
Results were presented as mean fold change in expression with and the error bar as standard error of the mean (SEM). * p<0.05 versus the
corresponding RV-1B alone. ^p<0.05 versus healthy RV-1B infected pBECs.
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(Figure 6A – B). However, IFN-λ1, CCL-5, and CXCL-
10 proteins were significantly induced in both healthy
and COPD pBECs after pre-treatment (Figure 6C – E).
The heightened antiviral responses also correlated with
significantly reduced viral titre with exogenous IFN-β/λ1
treatment (Additional file 1: Figure S3 of the online
supplement).Discussion
People with COPD are more susceptible to viral infec-
tion and suffer severe complications with worsened
symptoms and frequent exacerbations following infec-
tion. This study investigated the transcriptional response
of pBECs to RV infection and how this is altered in
COPD. We show that the immune response of healthy
and COPD cells was characterised by a robust up-
Figure 6 Inflammatory and antiviral proteins at 24 hours after RV-1B infection in IFN-β/λ1-pre-treated healthy (n=6) and COPD (n=6)
pBECs. IFN-β/λ1-pre-treatment before RV-1B infection led to a reduction of (A) IL-6 in healthy pBECs, but had no effect in COPD pBECs. (B)
Similarly TNF-α protein was not affected by IFNs pre-treatment. (C) IFN-λ1, (D) CCL-5, and (E) CXCL-10 was significantly induced in pre-treated
healthy and COPD pBECs. Results were presented as standard error of the mean (SEM). * p<0.05 versus the corresponding RV-1B. ^p<0.05 versus
healthy RV-1B infected pBECs.
Baines et al. Respiratory Research 2013, 14:15 Page 9 of 12
http://respiratory-research.com/content/14/1/15regulation of pro-inflammatory and antiviral pathways.
However there were clear differences between the
COPD and healthy pBECs, including up-regulation of
inflammatory genes at baseline and dramatically exag-
gerated responses to RV infection. We identified 9 genes
associated with COPD at baseline and 22 genes altered
in COPD but not healthy pBECs in response to RV, not
previously reported in COPD, but likely to be important
in regulating the exaggerated virus induced inflamma-
tion. The increased gene expression in RV infected COPD
pBECs also correlated with the corresponding protein re-
lease, and enhanced apoptosis; however this enhanced im-
mune response did not reduce viral titre. Furthermore,
IFN-β/λ1 pre-treatment resulted in enhanced responses to
RV-1B in COPD and healthy pBECs, however COPD
pBECs were unresponsive in terms of MDA-5/RIG-I and
IFN-β gene induction. Despite this abnormality IFN-β/λ1
pre-treatment still led to significantly reduced viral titre.
The airway epithelium in COPD is exposed chronically
to enhanced airway inflammation with increased num-
bers of neutrophils and lymphocytes that correlate with
more severe airflow obstruction, despite the fact that the
majority of subjects have ceased smoking, indicating thatthe airway inflammatory response in COPD becomes
self-perpetuating [11,12]. We found several novel asso-
ciations with 9 up-regulated genes in COPD pBECs, in-
cluding the calgranulins S100A8 and S100A9, and
proteases ADAM19 and MMP10. S100A8/A9 are small
calcium-binding proteins with pro-inflammatory activity
and have been reported to increase with steroid resistant
neutrophilic inflammation [13]. ADAM19 and MMP10
are involved in tissue repair and remodelling, and single
nucleotide polymorphisms in the gene locus containing
ADAM19 has been associated with COPD [14]. These
observations are consistent with other studies suggesting
that the airways of COPD subjects undergo constant cel-
lular repair due to the damages caused by cigarette
smoke exposure [1]. Interestingly MMP10 and ADAM19
gene expression has also been shown to be upregulated
in pBECs from subjects with asthma [15].
Upon RV-1B infection, both pBEC groups mounted a
robust inflammatory response; however the response
was more exaggerated in COPD pBECs. This was in ac-
cordance with other studies that showed a more vigo-
rous inflammatory response in COPD pBECs against RV
infection [16]. We have identified a number of novel
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COPD pBECs in response to RV-1B but not in healthy
pBECs. These include important signalling molecules
downstream of IL-1 and TLR2, 3 and 4 pathways such
as PELI1 [17], IRAK2 [18] and CH25H [19]. We have
previously shown that PELI1 and IRAK2 are up-
regulated in the sputum of subjects with neutrophilic
asthma [9]. This suggests that IRAK2 and PELI1 play a
role promoting neutrophilic airway inflammation, which
is triggered by RV infection of the epithelium in COPD.
Recently, PELI1 has been shown to be important in
regulating the innate immune response of the epithelium
to RV, including CXCL-8 production and neutrophil re-
cruitment, without interfering with IFN responses and
viral replication [20]. Mouse models have shown that
IRAK2 is critical in sustaining late phase inflammatory
responses after TLR stimulation, leading to increased
production of inflammatory cytokines [21]. These mole-
cules may also be important in T cell related functions,
such as T cell tolerance [22], and promotion of Th17 cell
development [23].
Other important signalling proteins induced by RV in
COPD pBECs include PMAIP1, ATF3 and GBP4.
PMAIP1, a mitochondria-associated protein, promotes
apoptosis [24]. ATF3 senses oxidative stress [25] and
functions to reduce TLR4-mediated NF-κB signalling,
therefore serving as negative feedback [26]. GBP4 is an
IFN-inducible GTPase that has been shown to disrupt
IRF7 activation, thereby inhibiting the induction of type
I IFNs [27]. Also potentially important is the up-
regulation of Chemokine (C-X3-C motif ) ligand 1
(CX3CL1), more commonly known as fractalkine, by
RV-1B in COPD pBECs. Soluble CX3CL1 has a chemo-
attractant activity for T cells and monocytes; whereas
membrane bound protein promotes adhesion of these
leukocytes [28].
Antiviral responses such as IFN-β and -λ1 are critical
in limiting viral replication, and were significantly higher
in COPD pBECs. This was associated with the higher
level of apoptosis after infection, but surprisingly did not
affect viral titre in COPD, which was similar to the
healthy group. This was in contrast to the study
by Schneider et al. that showed enhanced antiviral
responses associated with increased replication of RV-39
after infection in COPD [29]. Other studies have exam-
ined transcriptional responses to in vivo RV infection of
healthy controls using nasal epithelial scrapings [30], or
in vitro RV infection of healthy pBECs [31]. There are
many similarities between the changes in gene expres-
sion found in reported studies compared to the current
study, which includes upregulation of ISGs, antiviral
genes, chemokines, and cytokines. However there are
also differences in the healthy pBEC responses, including
some genes previously reported to be upregulated by RV(e.g. IFNB1, and IL6) that were unchanged in this study.
These differences are likely explained by altered experi-
mental conditions, such as differing strains of RV, cul-
ture or sampling methods including submerged culture
versus air-liquid interface culture versus in vitro infec-
tion, time points of RNA sampling, microarray platforms
and microarray analysis methods. Nevertheless, this well
controlled study adds significant knowledge regarding
the differences between healthy and COPD innate im-
mune responses to RV-1B infection under the conditions
investigated, which warrant further investigation.
The underlying mechanisms of unchanged viral repli-
cation despite induced antiviral responses in COPD
pBECs after RV-1B infection is currently unclear. It is
possible that the IFNs produced by infection did not effi-
ciently initiate the subsequent inductions of ISGs in
COPD pBECs, therefore leading to an unchanged viral
titre. However this would not explain the high apoptosis
induction in COPD pBECs by RV-1B infection and
marked reduction of RV-1B viral replication following
IFN pre-treatment. ISGs such as protein kinase R (PKR)
have been shown to induce apoptosis via the Fas-
associated death domain (FADD) [32], and induction of
which by RV-1B infection in COPD pBECs was higher
compared to that in healthy pBECs. Pre-treatment with
IFNs also significantly reduced viral replication, further
suggesting IFN signalling leading to ISG induction may
be functional in COPD. Nevertheless, it is also possible
that ISGs were ineffectively up-regulated in COPD
pBECs, and apoptosis could also have been induced by
other signalling pathways including TNF-α/TNFR1 path-
way [33], and compensated for the reduced ISGs pro-
duction. This may explain the excess tissue damage and
high inflammation that can be caused by high levels of
apoptosis in the airways of those with COPD [34].
While we showed a heightened inflammatory response
and antiviral response to RV infection in COPD pBECs
in this study, we also demonstrated defects in the anti-
viral pathway. IFN-β/λ1 pre-treatment led to increased
IL-6 and TNF-α mRNA in healthy pBECs, however this
was not translated to protein production which was
either reduced or unchanged with IFN-β/λ1 pre-treat-
ment. Previous studies have shown exogenous IFN-β
decreases RV-1B-induced IL-6 release from healthy and
asthmatic pBECs via an unidentified pathway [35]. IFN-
β/λ1 pre-treatment also enhanced antiviral responses in-
cluding MDA-5 and RIG-I, and IFN-β mRNAs in
healthy pBECs, leading to marked decrease in viral titre.
However, in COPD pBECs IFNs pre-treatment failed to
induce MDA-5 and RIG-I and IFN-β mRNA, but did
enhance CCL-5, CXCL-10, and IFN-λ1 production,
resulting in a decreased viral titre. This indicates that
MDA-5-initiated antiviral responses were partially
impaired in COPD and led to reduced IFN-β level. It is
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regulated ISGs such as PKR and MxA, that bound and
degraded viral RNAs as RV endocytosed into the host
cells. This also suggests differential signalling pathways
that regulate type III IFNs other than MDA-5/RIG-I and
IFN-β. Indeed, a recent study has identified a cluster of
NF-κB binding sites on human IFN-λ1 promoter, and
NF-κB was critical for IFN-λ1 induction but not for type
I IFNs expression [36]. This is consistent with our
results as both NF-κB and IFN-λ1were significantly up-
regulated in COPD pBECs.
Apoptosis is another important component of antiviral
responses, which was significantly increased in COPD
pBECs after RV infection. This may correlate with the
increased TNF and IFN levels [37], which can also up-
regulate PMAIP1 gene that promotes the induction of
apoptosis [24]. However increased apoptosis did not re-
duce viral titre. The reason for this observation is un-
clear; however, it is possible that the quantification
methods (TCID50) used in this study may not be as sen-
sitive as direct quantification methods such as plaque
assays. Detection of RV-1B by qPCR could only measure
the level of total viral RNAs and not differentiate live
from dead viruses. Alternatively, high levels of oxidative
stress could have contributed to this observation. Super-
oxide dismutase 2 (SOD2) and ATF3 are important anti-
oxidative genes that were up-regulated to a greater
extent in COPD pBECs after infection when compared
with infected healthy pBECs. Lack of SOD2 in mice can
lead to increased oxidative damage to DNA [38], and
lack of ATF3 alters DNA repair mechanisms [39]. This
indirectly indicates that the level of oxidative stress is
higher in RV infected COPD pBECs compared to that in
healthy cells.Conclusions
We have demonstrated that COPD pBECs elicit ex-
cessive pro-inflammatory and antiviral responses to
RV-1B infection. The greater expression of molecules
such as the calgranulins at baseline and pellino-1 and
IRAK2 after RV-1B infection may contribute to dysre-
gulated innate immune responses in the airways
and potentiation of inflammation as seen in COPD.
Additionally, MDA-5/RIG-I and IFN-β induction to
exogenous IFN-β/λ1 pre-treatment prior to infection
was impaired in COPD. However IFN-λ1 induction
by RV-1B infection was sufficient to limit replication
in COPD pBECs. This provides novel insight in the
immune responses in COPD pBECs to RV infection
and may reveal potential therapeutic targets that limit
the dysregulated inflammatory response due to RV
infection, without compromising antiviral defences in
COPD.Additional file
Additional file 1: Online Supplementary Material. Table S1. Subject
characteristics. FEV1% predicted refers to the forced expiratory volume in
1s expressed as a percentage of the predicated value. Table S2.
Differential gene expression of RV-1B infected COPD pBECs compared to
RV-1B infected healthy control pBECs. Figure S1. RV-1B viral replication
in healthy and COPD pBECs at 24hr after infection. RV-1B viral replication
was measured by (A) qPCR and by (B) TCID50 assay, and viral replication
was similarly observed in both healthy and COPD pBECs after infection.
Results were presented as standard error of the mean (SEM). Figure S2.
Viability, apoptosis, and necrosis induction after RV-1B infection. Host
cellular viability, apoptosis, and necrosis was determined in the infected
pBECs. (A) Healthy and COPD pBECs showed a significant reduction in
viability after infection, and this correlated with concomitant increase in
(B) apoptosis and (C) necrosis. Results were presented as standard error
of the mean (SEM). * indicates a significant difference compared to the
relative media control. ^ indicates a significant difference compared to
healthy pBECs media control. Figure S3. RV-1B viral replication in IFN-β/
λ1-pre-treated pBECs. (A) Viral RNAs was not affected at RNA levels,
however (B) viral replication by TCID50 assay showed a decrease in
replication with IFN-β/λ1 treatment. Results were presented as standard
error of the mean (SEM). * indicates a significant difference compared to
the relative media control.
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